The Pharma Data
MARCH 25, 2021
These findings represent the first comprehensive comparative effectiveness analysis of survival outcomes for a CDK 4/6 inhibitor in routine clinical practice and were published online in Breast Cancer Research. months with letrozole alone (HR 0.58: 95% CI, 0.49 months among patients in the letrozole group (HR 0.66: 95% CI, 0.53
The Pharma Data
FEBRUARY 8, 2021
IBRANCE is indicated for the treatment of adult patients with HR+, HER2- advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women or in men; or with fulvestrant in patients with disease progression following endocrine therapy. 2,3 In the U.S.,
The Pharma Data
APRIL 14, 2021
A global, randomized Phase 3 confirmatory clinical trial TROPiCS-04 (NCT04527991) is underway and is also intended to support global registrations. TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells. More information on TROPiCS-04 is available at [link]. About Trodelvy.
Expert insights. Personalized for you.
52 
Let's personalize your content